老虎證券

BRIEF-Lexicon To Reposition As Clinical Development-Focused Company Following Regulatory Update From FDA

Reuters
2024-11-22
BRIEF-Lexicon To Reposition As Clinical Development-Focused Company Following Regulatory Update From FDA

Nov 22 (Reuters) - Lexicon Pharmaceuticals Inc LXRX.O:

  • LEXICON TO REPOSITION AS CLINICAL DEVELOPMENT-FOCUSED COMPANY FOLLOWING REGULATORY UPDATE FROM FDA

  • LEXICON PHARMACEUTICALS INC: EFFORTS EXPECTED TO REDUCE 2025 OPERATING COSTS BY $100 MILLION

  • LEXICON PHARMACEUTICALS INC: PRIORITIZING STRONG RESEARCH AND DEVELOPMENT PIPELINE INCLUDING ONGOING STUDIES IN DPNP, HCM AND OBESITY

  • LEXICON PHARMACEUTICALS INC: IMPLEMENTING STRATEGIC RESTRUCTURING TO ELIMINATE COMMERCIAL ORGANIZATION AND RATIONALIZE OPERATIONS ACROSS ALL FUNCTIONS

  • LEXICON PHARMACEUTICALS INC: TOTAL REDUCTION OF APPROXIMATELY 60 PERCENT OF EMPLOYEES, EFFECTIVE FOR MOST AFFECTED EMPLOYEES BY DECEMBER 31

  • LEXICON PHARMACEUTICALS INC: ELIMINATION OF PROMOTIONAL EFFORTS FOR INPEFA, PLANNED COMMERCIAL ACTIVITIES FOR ZYNQUISTA

  • LEXICON PHARMACEUTICALS INC: RECEIPT OF A "DEFICIENCIES PRECLUDE DISCUSSION" LETTER FROM FDA REGARDING NDA FOR ZYNQUISTA

Source text: ID:nGNXnl2zP

Further company coverage: LXRX.O

((Reuters.Briefs@thomsonreuters.com;))

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10